The Non-clinical pharmacodynamic platform is underpinned by a highly skilled professional technical team, advanced equipment, and a comprehensive selection of cell banks and in vivo disease pharmacodynamic models. Leveraging a wealth of in vitro and in vivo pharmacological efficacy models, InnoStar offers a broad array of pharmacodynamic evaluations for new drug development across multiple levels—overall, cellular, molecular, and genetic. This ensures the acceleration of customer research projects by providing essential insights at the earliest stages of drug development.
InnoStar is committed to providing timely and convenient pharmacodynamic services for the research and development of new drugs
The pharmacodynamics platform boasts rich professional expertise and a vast breadth of experience in pharmacological applications. Over the years, the team has built an extensive and continuously improving library of tumor and non-tumor cell lines, as well as animal models. These capabilities allow InnoStar to provide highly effective pharmacological models tailored to the specific needs of clients. The platform includes a comprehensive range of tumor models (orthotopic transplantation, subcutaneous transplantation, humanized mouse models, and PDX models) and non-tumor disease models, offering services for a variety of drug types: small molecule compounds, peptides, antibody drugs (monoclonal, bispecific/multispecific antibodies, nanoantibodies, etc.), ADC, CGT products (immune cell therapy, stem cell therapy, oncolytic, viral, AAV vector gene therapies), nucleic acid drugs, vaccine products, radioactive drugs, and more.
The animal species utilized in these studies include mice, rats, rabbits, guinea pigs, minipigs, dogs, and non-human primates, providing a diverse and comprehensive platform for evaluating a broad spectrum of pharmaceutical products.
Copyright © 2017-2021©Shanghai InnoStar Bio-tech Co., Ltd. All Rights Reserved. Created By VPABrand.com